Back to News
Market Impact: 0.32
Corcept Grows to Mid-Cap on Institutional Support
Source: fxempire.com
Market Technicals & FlowsInvestor Sentiment & PositioningHealthcare & BiotechCompany Fundamentals
Corcept Therapeutics shares have risen 1,016% since 2017, driven by sustained large-volume institutional buying. The company is nearing inclusion in the S&P MidCap 400, a potential catalyst for additional index-fund demand and investor visibility.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
CORT0.78
More News
- Japan’s corporate leaders sound alarm over weak yen — even dollar-earners are voicing concerns
- Fed hikes again - an AI-Picked insurer is still cashing in
- Berkshire May Boost Japan Trading House Holdings, Itochu Says
- Investors react to Fed hike and market sell-off: Brace for 'higher for longer' rates
- Stocks slide toward lowest level since July after Warsh’s hawkish press conference
- Fed rate hike fails to calm troubled markets as Dow falls 600 points. Expect more sharp swings in stocks and bonds.